Licensure of meningitis vaccines is increasingly being made on the basis of safety and immunogenicity. For meningococcal vaccines, a measure of immunogenicity is seroconversion, usually defined as a four-fold increase in rSBA titre. However, this definition is likely to underestimate seroconversion in settings with high background immunity. Using data from a study of the immunogenicity of meningococcal polysaccharide vaccines undertaken in Ghana, a logistic regression model to estimate the probability of seroconversion as a function of pre-vaccination titre has been developed. The seroconversion rate (91%) based on a variable-fold increase in rSBA titre derived from the model was a more plausible estimate of immunogenicity than the seroconversion rate (32%) based on the fixed four-fold increase in rSBA.
Vaccine (2007) 25 (Supplement 1) A58-A62 [doi:10.1016/j.vaccine.2007.04.042]